Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
22/09/2026 13:57
BRIEF-Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027 Sept 22 (Reuters) - Natera, Inc. NTRA.O:
SIGNATERA™ RECEIVES REGULATORY APPROVAL IN JAPAN AS A COMPANION DIAGNOSTIC IN MUSCLE-INVASIVE BLADDER CANCER
NATERA- SIGNATERA COMMERCIAL LAUNCH IN JAPAN EXPECTED IN 1H 2027
Source text: ID:nBwc4n0gFa
Further company coverage: NTRA.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers